

## Revitalizing the Standardization of Criteria for Diagnosing Obstructive Ventilatory Impairment: A Crucial Call to Scholarly Societies (ATS, ERS, GINA, and GOLD) for Action

Fatma Guezguez<sup>1,2,3</sup> and Helmi Ben Saad<sup>1,2,3\*</sup>

<sup>1</sup>Physiology and Functional Explorations Department, Farhat HACHED Hospital, University of Sousse, Sousse, Tunisia

<sup>2</sup>Research Laboratory LR12SP09 "Heart Failure", Farhat HACHED Hospital, University of Sousse, Sousse, Tunisia

<sup>3</sup>Laboratory of Physiology, Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia

\*Corresponding Author: Helmi Ben Saad, Laboratory of Physiology, Faculty of Medicine of Sousse, Sousse, Tunisia.

Received: June 14, 2023; Published: August 02, 2023

### Abstract

The diagnosis of obstructive ventilatory impairment (OVI) is currently lacking worldwide consensus. This lack of agreement on the threshold for a significantly low ratio of forced expiratory volume in 1 second to forced vital capacity has led to ongoing debates and misperception among physicians and researchers. This review aims to update the definitions of OVI provided by scholarly societies, including the American Thoracic Society and European Respiratory Society (ATS/ERS), the Global Strategy for Prevention, Diagnosis, and Management of COPD (GOLD), and the Global Initiative for Asthma (GINA). Additionally, the review provides an overview of the rationales behind these definitions and highlights the challenges associated with spirometric indices and threshold selection. The call to action urges scholarly societies to standardize the criteria for diagnosing OVI. Two approaches were used by scholarly societies to define OVI: the physiological approach (ATS/ERS) and the operational approach (GOLD and GINA). Each approach utilizes different criteria and threshold values for diagnosing OVI, creating complexity for clinicians and researchers. The advantages and limitations of the physiological and operational approaches are discussed. The physiological approach offers increased specificity, early detection, and reduced false positives, but challenges in interpretation and limited application should be considered. The operational approach provides simplified diagnosis, aligns with clinical trial evidence, and facilitates screening and case finding. However, it increases the risk of misdiagnosis, it may lead to misclassification and challenges in interpreting results for different age groups, variability with sex and height, and potential misdiagnosis and adverse outcomes. It is recommended that ATS/ERS, GOLD, and GINA work towards proposing a standardized definition for OVI. By doing so, healthcare professionals can ensure consistent and effective diagnosis and management of OVI, ultimately improving patient care and outcomes.

**Keywords:** *Bronchial Asthma; Bronchial Obstruction; COPD; Diagnostic Criteria; Physiological Approach; Operational Approach; Spirometry*

### Abbreviations

ATS: American Thoracic Society; COPD: Chronic Obstructive Pulmonary Disease; ERS: European Respiratory Society; FEV<sub>x</sub>: Forced Expiratory Volume in x Second; FVC: Forced Vital Capacity; GINA: Global Initiative for Asthma; GLI: Global Lung Function Initiative; GOLD: Global

**Citation:** Fatma Guezguez and Helmi Ben Saad. "Revitalizing the Standardization of Criteria for Diagnosing Obstructive Ventilatory Impairment: A Crucial Call to Scholarly Societies (ATS, ERS, GINA, and GOLD) for Action". *EC Pulmonology and Respiratory Medicine* 12.7 (2023): 01-11.

Strategy for Prevention, Diagnosis, and Management of COPD; LLN: Lower Limit of Normal; OVI: Obstructive Ventilatory Impairment; SVC: Slow Vital Capacity

## Introduction

The global prevalence of chronic obstructive pulmonary disease (COPD) and bronchial asthma is steadily increasing [1,2]. Both of these chronic diseases are characterized by obstructive ventilatory impairment (OVI), which necessitates the use of precise diagnostic methods such as spirometry [1-3]. Conventionally, the diagnosis of OVI is based on an abnormally low ratio between forced expiratory volume in 1 second ( $FEV_1$ ) and forced vital capacity (FVC) [1-9]. The presence of a significantly low  $FEV_1/FVC$  ratio is considered the gold standard for confirming the diagnosis of OVI [1-9]. However, there is currently no worldwide consensus on what constitutes a significantly low  $FEV_1/FVC$  ratio [1-9]. As of June 13, 2023, there is a lack of agreement on the threshold that best defines a significantly low ratio, leading to ongoing debates [1-9]. Consequently, the medical community lacks a clear consensus on the definition and criteria for identifying OVI, causing misperception and potential misdiagnosis for physicians and pulmonary researchers [4,10-12].

The aims of this review were to i) Update the definitions of OVI used by various scholarly societies, including the American Thoracic Society and European Respiratory Society (ATS/ERS) [3], the Global Strategy for Prevention, Diagnosis, and Management of COPD (GOLD) [1], and the Global Initiative for Asthma (GINA) [2]; and ii) Provide a brief overview of the rationales behind the different definitions [1-3]. This review serves as a crucial call to scholarly societies such as ATS/ERS, GINA, and GOLD, urging them to take action and revitalize the standardization of criteria for diagnosing OVI.

## How scholarly societies define OVI in 2023?

Scholarly societies have established two approaches to define OVI: a physiological approach (ATS/ERS) [3] and an operational approach (GOLD and GINA) [1,2] (Box 1). The ATS/ERS [3] utilizes a physiological approach by defining OVI as a  $FEV_1/FVC$  ratio under the 5<sup>th</sup> percentile [i.e. lower limit of normal (LLN) range or a z-score < -1.645] derived from reference values that consider age and sex [13]. The ATS/ERS [3] suggests adjusting the LLN lower when spirometry is performed in low-risk populations, such as general screening, to reduce the number of false positives. They propose conservative LLNs of 2.5% (z-score < -1.965) or even 1% (z-score < -2.326) [3]. GOLD adopts an operational approach, using a fixed value of 0.70 (post-bronchodilator  $FEV_1/FVC < 0.70$ ) [1]. However, GOLD provides further guidance for two scenarios related to the initial value of the post-bronchodilator  $FEV_1/FVC$  ratio measured on a single spirometric test [1]. First, if the ratio falls between 0.60 and 0.80, OVI should be established by repeat spirometry on a distinct visit to account for biological variation [1]. Second, when the initial ratio is <0.60, it is highly improbable to increase naturally above 0.70, and the diagnosis of OVI (and therefore COPD) is confirmed [1]. GINA follows an operational approach using fixed threshold values of 0.75 to 0.80 in adults and 0.90 in children [2]. GINA recommends comparing the reduced  $FEV_1$  with the LLN and confirming that the  $FEV_1/FVC$  ratio is typically > 0.90 in children and > 0.75 - 0.80 in adults [2] based on the multi-ethnic reference values for spirometry established by the Global Lung Function Initiative (GLI) 2012 equations [13]. These three different definitions have created complexity for clinicians and researchers alike.

## Rationales behind the retained definitions?

The following three points need to be briefly highlighted: i) Should we use  $FEV_1/FVC$  or  $FEV_1$ /slow vital capacity (SVC) as the preferred spirometric index for assessing OVI? ii) Are there other alternative spirometric indices that have been proposed to assess OVI? And iii) Which approach (physiological or operational) and which threshold to apply?

## $FEV_1/FVC$ or $FEV_1/SVC$ ?

Among the discussed three scholarly societies, only ATS/ERS [3] addresses the use of  $FEV_1/SVC$  in assessing OVI (Box 1).

Scholarly societies, Year	Approach and definition	Alternative indices
ATS/ERS 2022 [3]	<ul style="list-style-type: none"> <li>Physiological approach: z-score FEV<sub>1</sub>/FVC:                             <ul style="list-style-type: none"> <li>&lt; -1,645: Individuals with elevated risk</li> <li>&lt; -1,96 or &lt; -2.326: Screening the general population</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>FEV<sub>1</sub>/SVC?</li> <li>FEV<sub>1</sub>/FEV<sub>6</sub>?</li> <li>FEV<sub>1</sub>/FEV<sub>3</sub>?</li> <li>FEV<sub>1</sub>/FEV<sub>2</sub>?</li> <li>FEV3/FV6?</li> <li>FEV3/FVC?</li> <li>Inspiratory capacity</li> <li>Flow-volume loop' slope</li> <li>Flow-volume loop' curvature</li> <li>Raw, sRaw, sGaw: body plethysmography</li> <li>Oscillometry</li> </ul>
GOLD 2023 [1]	<ul style="list-style-type: none"> <li>Operational approach: Post-BD FEV<sub>1</sub>/FVC &lt; 0.70</li> <li>2 situations related to the initial value of the post-BD FEV<sub>1</sub>/FVC ratio:                             <ul style="list-style-type: none"> <li>Between 0.60 and 0.80: OVI should be confirmed by repeat spirometry on a separate occasion</li> <li>&lt; 0.60: OVI retained</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Not applied</li> </ul>
GINA 2023 [2]	<ul style="list-style-type: none"> <li>Operational approach: FEV<sub>1</sub>/FVC                             <ul style="list-style-type: none"> <li>&lt; 0.75: Adults</li> <li>&lt; 0.90: Children</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Not applied</li> </ul>

ATS/ERS: American Thoracic Society and European Respiratory Society; BD: Bronchodilator; FEV<sub>x</sub>: Forced Expiratory Volume in x Second; FVC: Forced Vital Capacity; GINA: Global Initiative for Asthma; GOLD: Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease; Raw: Airway Resistance; sGaw: Specific Airway Conductance; sRaw: Specific Raw; SVC: Slow Vital Capacity.

**Box 1:** Definitions of obstructive ventilatory impairment (OVI) according to some scholarly societies.

According to ATS/ERS [3], using the largest vital from either SVC or FVC in place of FEV<sub>1</sub>/FVC for diagnosing OVI may increase sensitivity but decrease specificity compared to FEV<sub>1</sub>/FVC [14]. In healthy individuals, FVC and SVC do not significantly differ [13]. However, if SVC exceeds FVC by more than 100 mL, it suggests airway collapse during forced exhalation [3]. The use of FEV<sub>1</sub>/SVC to diagnose OVI introduces uncertainty, particularly in the older population. Therefore, ATS/ERS [3] recommends using FVC for the FEV<sub>1</sub>/FVC ratio because i) Both measurements should be obtained from forced expiratory maneuvers using identical equipment, and ii) Accurate norms are available for FEV<sub>1</sub>/FVC but not for FEV<sub>1</sub>/SVC.

**Utility of some alternative spirometric indices assessing OVI**

Among the discussed scholarly societies, only ATS/ERS [3] addressed the utility of alternative spirometric indices for assessing OVI (Box 1). First, ATS/ERS [3] suggests that some forced expiratory volume in x seconds, such as FEV<sub>6</sub>, FEV<sub>3</sub>, or FEV<sub>2</sub>, may be used as substitutes for FVC and show accuracy in diagnosing OVI, provided appropriate LLNs for FEV<sub>1</sub>/FEV<sub>6</sub>, FEV<sub>1</sub>/FEV<sub>3</sub>, and FEV<sub>1</sub>/FEV<sub>2</sub> are used (which is not the case with the GLI equations) [13]. Second, ATS/ERS [3] introduces inspiratory capacity, derived from spirometry, as another measure of OVI. Third, ATS/ERS [3] describes several other indices resulting from examination of the forced expiratory maneuver, including data of the slope or curvature of the flow/volume loop. Fourth, ATS/ERS [3] reports that additional measurements of airway function obtained through body plethysmography (e.g. airway resistance, specific airway resistance, or specific airway conductance) may complement spirometry in assessing OVI, particularly in children and individuals with early signs of lung disease, where spirometry values can appear normal despite confirmed disease. However, as stated by ATS/ERS [3], these measurements are not commonly used for identifying OVI. Finally, in individuals incapable to achieve a maximal forced expiratory maneuver, ATS/ERS [3] suggests that measuring respiratory system resistance using non-invasive oscillometry procedures may be useful.

**Which approach and which threshold to apply?**

For each approach, its rationale, its strong points (advantages) and its limitations (inconvenient) will be discussed below (Box 2). It is important to note that the advantages and limitations provided in box 2 are general observations and may not cover all specific aspects or considerations associated with each approach. The choice between the operational and physiological approaches should be carefully considered, taking into account the specific clinical context and available evidence.

	<b>Physiological approach (ATS/ERS [3])</b>	<b>Operational approach (GOLD [1], GINA, [2])</b>
Rationale	<ul style="list-style-type: none"> <li>Compares individual spirometry parameters with reference values</li> </ul>	<ul style="list-style-type: none"> <li>Uses fixed threshold values for diagnosing OVI</li> </ul>
Strong points	<ul style="list-style-type: none"> <li>Increased specificity: Considers age-related changes in the FEV<sub>1</sub>/FVC ratio, leading to greater specificity in diagnosing OVI</li> <li>Early detection: Capable of detecting OVI in the early stages, especially in younger adults or children, before the FEV<sub>1</sub>/FVC falls below the fixed threshold of 0.70.</li> <li>Reduced false positives: Leads to fewer false-positive diagnoses in the elderly population, where the FEV<sub>1</sub>/FVC naturally decreases due to aging.</li> </ul>	<ul style="list-style-type: none"> <li>Simplified diagnosis: Easy to remember and apply in clinical practice, providing consistency across different settings.</li> <li>Clinical trial evidence: Aligns with variables measured in clinical trials, facilitating translation of research findings into practice.</li> <li>Screening and case finding: Serves the purpose of quick assessment of OVI across different age groups by general practitioners and specialists.</li> <li>Limited risk of misdiagnosis: Acknowledges that spirometry is only one component of clinical diagnosis, reducing risk of misdiagnosis and over-treatment based solely on spirometry results.</li> </ul>

Limitations	<ul style="list-style-type: none"> <li>• Challenges in interpretation: Literal interpretation of functional impairment may be too simplistic when FEV<sub>1</sub>/FVC ratio is close to the LLN</li> <li>• Limitation of application: Lack of spirometric norms for many countries, but the GLI multi-ethnic reference equations have addressed this limitation.</li> <li>• Errors in interpretation: LLN values highly dependent on the choice of reference equations and race/ethnicity</li> </ul>	<ul style="list-style-type: none"> <li>• Age-related variations: May under-diagnose OVI in young adults and over-diagnose it in the elderly, particularly in mild disease.</li> <li>• Variability with sex and height: Fixed cutoffs do not account for observed changes in FEV<sub>1</sub>/FVC ratio variability with sex and height, potentially resulting in misinterpretation for women.</li> <li>• Misdiagnosis and adverse outcomes: Potential underdiagnosis and adverse outcomes when individuals classified as having OVI based on physiological approach but not meeting operational approach.</li> <li>• Presence of inexpensive pocket spirometers: The argument that fixed cutoffs are easy to remember is not justified, as even inexpensive pocket spirometers compute predicted FEV<sub>1</sub> and FEV<sub>1</sub>/FVC, as well as the LLN.</li> <li>• Conflict with reference data: Thresholds proposed by GINA conflict with statements from the GLI, which discourages the use of fixed thresholds due to age, height, and sex biases. The GINA thresholds also do not consider the biphasic trend of FEV<sub>1</sub>/FVC ratio in childhood and adolescence.</li> </ul>
<p>ATS/ERS: American Thoracic Society and European Respiratory Society; FEV<sub>1</sub>: Forced Expiratory Volume in 1 Second; FVC: Forced Vital Capacity; GINA: Global Initiative for Asthma; GOLD: Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease.</p>		

**Box 2:** Rational, strong points and limitations of the physiological and operational approaches adopted to define an obstructive ventilatory impairment (OVI) according to some scholarly societies.

**Physiological approach: ATS/ERS [3]**

The physiological approach adopted by ATS/ERS [3] for interpreting spirometry data is based on comparing individual parameters with reference values [15]. In this approach, values below the LLN, defined as the 5<sup>th</sup> percentile, are qualified abnormally low [3]. This method is appropriate as it focuses on determining whether the calculated FEV<sub>1</sub>/FVC ratio is significantly low. This approach has several arguments supporting its use but also has limitations that should be considered.

Advantages of the physiological approach include:

- i) Increased specificity:** By considering age-related variations in the FEV<sub>1</sub>/FVC ratio [13], the physiological approach offers greater specificity in diagnosing OVI.

**Citation:** Fatma Guezguez and Helmi Ben Saad. “Revitalizing the Standardization of Criteria for Diagnosing Obstructive Ventilatory Impairment: A Crucial Call to Scholarly Societies (ATS, ERS, GINA, and GOLD) for Action”. *EC Pulmonology and Respiratory Medicine* 12.7 (2023): 01-11.

- ii) Early detection:** The approach is capable of detecting OVI in the early stages of the disease, especially in younger adults or children, before the  $FEV_1/FVC$  falls below the fixed threshold of 0.70 [6].
- iii) Reduced false positives:** In the elderly population, where the  $FEV_1/FVC$  naturally decreases below 0.70 due to aging, the physiological approach leads to fewer false-positive diagnoses [16].

Limitations of the physiological approach include:

- i) Challenges in interpretation:** Challenges arise when the  $FEV_1/FVC$  ratio is close to its LLN [15]. In such cases, a literal reading of functional impairment may be too basic, and additional tests, such as bronchodilator testing, should be performed to provide a more comprehensive assessment [15].
- ii) Limitation of application:** The use of the physiological approach may be limited by the absence of spirometric norms for numerous countries [4,17], although the GLI multiethnic reference equations recommended since 2012 have addressed this limitation [13]. The GLI equations, based on data from a large and diverse population, provide more precise definitions of LLN using z-scores and are independent of ethnicity except for South East Asians [13].
- iii) Errors in interpretation:** Since the LLN depends on the reference equation used for the interpretation [18,19], errors in interpretation can occur if inappropriate norms are used [18]. According to GOLD [1], LLN values depend on the norms as well as ethnicity/race, and there is a lack of longitudinal studies certifying the use of the LLN.

In summary, while the physiological approach offers advantages such as specificity, early detection, and reduced false positives, challenges related to interpretation near the LLN and the availability of appropriate reference equations should be considered. The use of the GLI equations has improved the application of the physiological approach in diverse populations [13].

### **Operational approach: GOLD [1] and GINA [2]**

The operational approach, as advocated by GOLD [1] and GINA [2], relies on fixed threshold values for diagnosing OVI. This approach utilizes a similar rationale as the one used for diagnosing other chronic conditions like arterial hypertension or diabetes mellitus, where it is established that using fixed cut-offs is effective [20], so that a fixed cut-off for  $FEV_1/FVC$  should also yield reliable results [21]. However, normal blood pressure and glucose levels are tightly regulated within a narrow range by physiological control mechanisms. In contrast, there is no comparable system governing the level of  $FEV_1/FVC$ , leading to the acceptance that there is no specific target value for  $FEV_1/FVC$  [20].

The GINA proposed thresholds for adults and children have been approximately derived from the curve displaying the mean  $FEV_1/FVC$  as a function of age [2]. This operational approach, which is widely used in clinical studies [6], has several advantages but also some limitations that should be considered.

Advantages of the operational approach include:

- i) Simplified diagnosis:** The use of a single number (e.g. 0.70 for GOLD [1], 0.75 and 0.90 for GINA [2]) makes the diagnosis of OVI easy to remember and apply in clinical practice [22]. This simplicity is valued by busy clinicians [22] and allows for consistency across different settings. These qualities lend the 0.70 threshold, for example, to practical use in the recognition of COPD in any state [10].
- ii) Clinical trial evidence:** The operational approach aligns with the variables measured in clinical trials, which form the basis for treatment recommendations [1]. This consistency facilitates the translation of research findings into clinical practice [1]. The usage

of the operational approach is linked with augmented mortality, while the usage of the physiological one is not [23]. In this regard, it has been shown that individuals who were classified as having an OVI using a fixed threshold (i.e. 0.70) but normal using the 5<sup>th</sup> percentile had a high probability of disease with more respiratory symptoms, a significantly lower diffusion capacity, more exertional dyspnoea and poor exercise tolerance, more emphysema, gas trapping and airway wall thickening on computed tomography than those without OVI [9,24,25]. These results are in favour of the superiority of the operational approach over the physiological approach at least for the COPD diagnosis. Moreover, using the operational approach (e.g. fixed ratio) is not inferior to the physiological approach (e.g. LLN) regarding prognosis [26].

- iii) Screening and case finding:** The operational approach serves the purpose of screening by providing a quick assessment of OVI. It can be used across different age groups by general practitioners and specialists from other disciplines.
- iv) Limited risk of misdiagnosis:** The operational approach acknowledges that spirometry is only one component of the clinical diagnosis of OVI, and additional assessments are necessary to establish a comprehensive evaluation. This reduces the risk of misdiagnosis and over-treatment based solely on spirometry results.

In 2010, a letter was sent to GOLD criticizing the operational approach, and the signatories urged committee members to abandon this approach in favor of the physiological approach [27-31]. Limitations of the operational approach include:

- i) Age-related variations:** The fixed threshold values, such as 0.70 for FEV<sub>1</sub>/FVC, may over-diagnose OVI in the elderly, particularly in mild disease, and under-diagnose it in young adults [1]. This leads to potential misclassification and challenges in interpreting results for different age groups including elderly subjects and children [1]. The ATS/ERS [3] strongly discouraged the use of the 0.70 threshold for the FEV<sub>1</sub>/FVC ratio, and qualified it as a “rule of thumb”. The 0.70 threshold only approximates the LLN in the mid-range of age, where case finding of OVI or screening it is most likely to be performed. The LLN drops under a ratio of 0.70 from 45 years of age [27-31]. By disregarding the fact that the FEV<sub>1</sub>/FVC ratio naturally varies with age, even among non-smokers who have remained healthy throughout their lives [32], the prevalence of OVI is underestimated in younger individuals and overestimated in older individuals [4,16,33,34]. The 0.70 cut-offs causes up to 50% over-diagnosis above 45 years of age [27-31], and led to systematic misinterpretation of results for children [3]. In other studies, it appears that the fixed threshold resulted in underdiagnosis of COPD whatever the age was [4].
- ii) Variability with sex and height:** The fixed cutoffs do not account for the observed changes in FEV<sub>1</sub>/FVC ratio variability with sex and height [35]. For instance, the use of 0.70 cut-off resulted in consistent misinterpretation of results for women [3].
- iii) Misdiagnosis and adverse outcomes:** Some studies have shown that individuals classified as having OVI based on the physiological approach (i.e. FEV<sub>1</sub>/FVC ratio < 5<sup>th</sup> percentile) but not meeting the operational approach (i.e. FEV<sub>1</sub>/FVC ratio > 0.70) exhibit symptoms and markers of disease, suggesting potential underdiagnosis and adverse outcomes. This raises concerns about the superiority of the operational approach over the physiological approach [7,8].
- iv) Presence of inexpensive pocket spirometers:** The justification for using fixed cutoffs of 0.70, 0.75, and 0.90 based on their ease of memorization is unfounded since even affordable pocket spirometers calculate predicted values for FEV<sub>1</sub> and FEV<sub>1</sub>/FVC, as well as the LLN [20].
- v) Conflict with reference data:** The thresholds proposed by GINA [2] (Box 1) conflict with statements from the GLI [13], which discourages the use of fixed thresholds due to age, height, and sex biases. The GINA thresholds fail to take into account the biphasic trend observed in the FEV<sub>1</sub>/FVC during growth (i.e. childhood and adolescence) [13]. In practice, the 5<sup>th</sup> percentile for FEV<sub>1</sub>/FVC vary with age and is clearly different from the threshold values proposed by GINA [2].

In conclusion, the operational approach has advantages such as simplicity and consistency but is also associated with limitations related to age-related variations, lack of physiological regulation, misdiagnosis, and conflict with reference data.

### **What should be done in future?**

In the future, the following actions are recommended:

- i) Conduct higher-quality prospective studies [3,17,36]:** More research is needed to clearly define what constitutes an OVI, considering the smoking status of individuals [4,10,11]. These studies should aim to establish an unambiguous consensus on OVI diagnosis and compare different approaches in terms of their effectiveness in identifying the disease.
- ii) Comparative analysis of different definitions:** It is important to compare the various diagnostic approaches and definitions in terms of their ability to accurately identify individuals with OVI. Research should focus on assessing the probability of having the disease using different approaches to determine which performs better [7-9,16,24,25].
- iii) Investigation of artificial intelligence and machine learning techniques:** Their use, in the context of analyzing the expiratory flow/volume loop may offer improved precision in evaluating small airway function. Further research should investigate the potential of these techniques in improving the diagnosis and understanding of OVI [3,37].

By pursuing these future steps, it is possible to enhance the understanding and diagnosis of OVI, leading to improved patient care and outcomes.

### **Conclusion**

In conclusion, the standardization of the OVI definition is a complex issue that requires a balance between population-based approaches and individual patient perspectives [38]. The selection of an appropriate definition should prioritize the benefit to the patient in terms of early disease management, while avoiding overdiagnosis and unnecessary costs. It is recommended that scientific organizations and professional societies revisit evidence-based medicine principles, revise their guidelines, and work towards proposing a standardized definition for OVI. By doing so, healthcare professionals can ensure consistent and effective diagnosis and management of OVI, ultimately improving patient care and outcomes.

### **Acknowledgments**

We would like to express our sincere gratitude for the invaluable assistance provided by the language model, CHATGPT, in the correction and improvement of our scientific paper.

### **Conflicting Interest**

None.

### **Authors' Contributions**

FG, HBS: Manuscript preparation and Review of manuscript.

Both authors read and approved the final manuscript.

### **Sources of Financial Support**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### **Bibliography**

1. Agustí A, et al. "Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary". *American Journal of Respiratory and Critical Care Medicine* 207.7 (2023): 819-837.



2. GINA. Global strategy for asthma management and prevention (2023).
3. Stanojevic S., *et al.* "ERS/ATS technical standard on interpretive strategies for routine lung function tests". *European Respiratory Journal* 60.1 (2022): 2101499.
4. Affes Z., *et al.* "Defining obstructive ventilatory defect in 2015". *Libyan Journal of Medicine* 10.1 (2015): 28946.
5. Reyes-Garcia A., *et al.* "Controversies and limitations in the diagnosis of chronic obstructive pulmonary disease". *Revista de Investigación Clínica* 71.1 (2019): 28-35.
6. Bhatt SP. "Diagnosis of chronic obstructive pulmonary disease: Breathing new life into an old debate". *Annals of the American Thoracic Society* 15.2. (2018): 163-165.
7. Van Dijk W., *et al.* "Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort". *Annals of Family Medicine* 13.1 (2015): 41-48.
8. Wollmer P and Engstrom G. "Fixed ratio or lower limit of normal as cut-off value for FEV1/VC: an outcome study". *Respiratory Medicine* 107.9 (2013): 1460-1462.
9. Wollmer P., *et al.* "Fixed ratio or lower limit of normal for the FEV(1)/VC ratio: relation to symptoms and extended lung function tests". *Clinical Physiology and Functional Imaging* 37.3 (2017): 263-269.
10. Ben Saad H., *et al.* "Which definition to use when defining airflow obstruction?". *La Revue des Maladies Respiratoires* 24.3-1 (2007): 323-330.
11. Kammoun R., *et al.* "Defining and grading an obstructive ventilatory defect (OVD): 'FEV (1)/FVC lower limit of normal (LLN) vs. Z-score' and 'FEV (1) percentage predicted (%pred) vs. Z-score'". *Libyan Journal of Medicine* 13.1 (2018): 1487751.
12. Saad HB., *et al.* "The diagnosis of COPD is recommendation dependent". *La Tunisie Médicale* 92.7 (2014): 474-481.
13. Quanjer PH., *et al.* "Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations". *European Respiratory Journal* 40.6 (2012): 1324-1343.
14. Saint-Pierre M., *et al.* "Is the slow vital capacity clinically useful to uncover airflow limitation in subjects with preserved FEV (1)/FVC ratio?" *Chest* 156.3 (2019): 497-506.
15. Crapo RO. "Role of reference values in making medical decisions". *Indian Journal of Medical Research* 122.2 (2005): 100-102.
16. Güder G., *et al.* "GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study". *Respiratory Research* 13.1 (2012): 13.
17. Pellegrino R., *et al.* "Interpretative strategies for lung function tests". *European Respiratory Journal* 26.5 (2005): 948-968.
18. Ben Saad H., *et al.* "The recent multi-ethnic global lung initiative 2012 (GLI2012) reference values don't reflect contemporary adult's North African spirometry". *Respiratory Medicine* 107.12 (2013): 2000-2008.

19. Stanojevic S., *et al.* "The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF registry". *The Journal of Cystic Fibrosis* 13.3 (2014): 319-327.
20. Enright P and Brusasco V. "Counterpoint: should we abandon FEV (1)/FVC < 0.70 to detect airway obstruction? Yes". *Chest* 138.5 (2010): 1040-1042.
21. Celli BR and Halbert RJ. "Point: should we abandon FEV (1)/FVC <0.70 to detect airway obstruction? No". *Chest* 138.5. (2010): 1037-1040.
22. Viegi G., *et al.* "Prevalence of airway obstruction in a general population". *Chest* 117. (2000): 339S-345S.
23. Mannino DM., *et al.* "Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?" *Thorax* 62.3 (2007): 237-241.
24. Mohamed Hoesein FA., *et al.* "Computed tomography structural lung changes in discordant airflow limitation". *PLoS One* 8.6 (2013): e65177.
25. Neder JA., *et al.* "Exercise tolerance according to the definition of airflow obstruction in smokers". *American Journal of Respiratory and Critical Care Medicine* 202.5 (2020): 760-762.
26. Bhatt SP., *et al.* "Discriminative accuracy of FEV1:FVC thresholds for COPD-related hospitalization and mortality". *The Journal of the American Medical Association* 321.24 (2019): 2438-2447.
27. Quanjer PH., *et al.* "Open letter to the members of the GOLD committee". *La Revue des Maladies Respiratoires* 27.9 (2010): 1003-1007.
28. Quanjer PH. "Open letter to the members of the GOLD committee". *Respiration* 80.4 (2010): 265-268.
29. Quanjer PH., *et al.* "The need to change the method for defining mild airway obstruction". *European Respiratory Journal* 37.3 (2011): 720-722.
30. Quanjer PH., *et al.* "Open letter: the need to change the method for defining mild airway obstruction". *Primary Care Respiratory Journal* 19.3 (2010): 288-291.
31. Quanjer PH., *et al.* "The GOLD guidelines definition of mild airway obstruction". *Respiratory Care* 55.10 (2010): 1397-1398.
32. Roberts SD., *et al.* "FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age". *Chest* 130.1 (2006): 200-206.
33. Stanojevic S., *et al.* "Reference values for lung function: past, present and future". *European Respiratory Journal* 36.1. (2010): 12-19.
34. Swanney MP., *et al.* "Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction". *Thorax* 63.12 (2008): 1046-1051.
35. Quanjer PH., *et al.* "Defining airflow obstruction". *European Respiratory Journal* 45.2. (2015): 561-562.

36. Celli BR, *et al.* "An official American Thoracic Society/European Respiratory Society statement: research questions in COPD". *European Respiratory Journal* 45.4 (2015): 879-905.
37. Bodduluri S, *et al.* "Deep neural network analyses of spirometry for structural phenotyping of chronic obstructive pulmonary disease". *JCI Insight* 5.13 (2020): e132781.
38. Neder JA. "The new ERS/ATS standards on lung function test interpretation: some extant limitations". *European Respiratory Journal* 60.2 (2022): 2200252.

**Volume 12 Issue 7 July 2023**

**©All rights reserved by Fatma Guezguez and Helmi Ben Saad.**